BBI News and Press, Brickell Biotech Inc. From 10/27/21

3 Penny Stocks That Could Explode in November 2021 If you’re looking for penny stocks that could explode, there are hundreds of options to choose from. And while part of finding penny stocks to buy is looking at fundamentals, the main cause of movement tends to be speculation...

Sofpironium bromide gel, 15% was generally well-tolerated Plan to submit a New Drug Application (NDA) to the FDA in mid-2022 Management to host webcast and conference call today at 8:30 a.m. ET to present the topline results BOULDER, Colo., Oct. 07, 2021 (GLOBE NEWSW...

BOULDER, Colo., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatol...

BOULDER, Colo., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatol...

BOULDER, Colo., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutic...

Expect to initiate Phase 1 clinical study of lead DYRK1A inhibitor program, BBI-02, a potential first-in-class oral treatment for autoimmune and inflammatory diseases, in 2022 Acquisition includes rights to platform of DYRK1A inhibitors with potential to create next generation k...

Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected to be reported in Q4 2021 NDA submission for sofpironium bromide gel, 15% anticipated in mid-2022 pending Phase 3 outcome BOULDER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc...

Start Time: 16:30 End Time: 16:47 Brickell Biotech, Inc. (BBI) Q2 2021 Earnings Conference Call August 12, 2021, 16:30 PM ET Company Participants Robert Brown - CEO Deepak Chadha - Chief R&D Officer Bert Marchio - CFO Garth Russell - Investor Relations, LifeSci Advisors Conference Call Pa...

Final patient has completed the Phase 3 pivotal Cardigan I study; Enrollment completed in Phase 3 pivotal Cardigan II study - - - Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected to be reported in Q4 2021 - - - Recent $8.1 million cap...

BOULDER, Colo., July 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced...